<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03038308</url>
  </required_header>
  <id_info>
    <org_study_id>AAAI8604</org_study_id>
    <secondary_id>1R21DK112093-01</secondary_id>
    <nct_id>NCT03038308</nct_id>
  </id_info>
  <brief_title>Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole</brief_title>
  <official_title>Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist&#xD;
      ropinirole for the treatment of hyperprolactinemia in patients with idiopathic&#xD;
      hyperprolactinemia and prolactinomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of prolactin secreting pituitary tumors with traditional ergot dopamine agonist&#xD;
      drugs can be limited by medication side effects, pharmacologic resistance, and by concerns&#xD;
      regarding the potential risk of cardiac valve disease. The overall goal of this project is&#xD;
      therefore to evaluate, for the first time, the efficacy and tolerability of the selective&#xD;
      D2/D3 receptor non-ergot dopamine agonist ropinirole for the treatment of prolactinomas. This&#xD;
      proposal will establish the pharmacologic profile of this medication when used to treat&#xD;
      hyperprolactinemia in patients with prolactinomas and will determine the impact of long-term&#xD;
      ropinirole administration on critical clinical parameters including serum prolactin levels,&#xD;
      gonadal function, and tumor regression, in order to establish ropinirole's utility as a new,&#xD;
      clinically efficacious, safer and more tolerable therapeutic option for the treatment of&#xD;
      prolactinomas that may prove particularly useful in patients with underlying cardiac valve&#xD;
      disease and in those with resistance or intolerance to ergot dopamine agonists.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 16, 2016</start_date>
  <completion_date type="Actual">November 5, 2020</completion_date>
  <primary_completion_date type="Actual">November 5, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>1) Forced titration dose response PKPD study and 2) A prospective open-label outpatient dose escalation trial of ropinirole for treatment of prolactinomas and hyperprolactinemia.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-label studies</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects That Achieved Stable PRL Normalization</measure>
    <time_frame>6-12 months</time_frame>
    <description>Serum prolactin concentrations (PRL levels) were measured in patients at baseline and at follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unchanged Tumor Size</measure>
    <time_frame>6-12 months</time_frame>
    <description>Radiologic assessment of tumor size before and after treatment will be made by MRI.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hyperprolactinemia</condition>
  <condition>Prolactinoma</condition>
  <arm_group>
    <arm_group_label>ROP Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropinirole</intervention_name>
    <description>0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole</description>
    <arm_group_label>ROP Intervention</arm_group_label>
    <other_name>ROP therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 18-70 years&#xD;
&#xD;
          -  Prolactin level (PRL) ≥2 times upper limit of normal&#xD;
&#xD;
          -  Pituitary adenomas on MRI ≤ 1.5cm in greatest diameter and ≥ 5mm from the optic chiasm&#xD;
&#xD;
          -  Normal renal and liver function&#xD;
&#xD;
          -  Agrees to barrier contraception if pre-menopausal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of medications known to interfere with PRL secretion and PRL and Ropinirole (ROP)&#xD;
             metabolism&#xD;
&#xD;
          -  Use of another dopamine agonist during the 4 weeks prior&#xD;
&#xD;
          -  Pituitary stalk compression on MRI&#xD;
&#xD;
          -  History of visual field abnormalities or previous radiation&#xD;
&#xD;
          -  Untreated hypothyroidism&#xD;
&#xD;
          -  Consumption of &gt; 2 alcoholic drinks per day&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabrielle Page-Wilson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Liu S, Hu C, Peters J, Tsang A, Cremers S, Bies R, Page-Wilson G. Pharmacokinetics and pharmacodynamics of ropinirole in patients with prolactinomas. Br J Clin Pharmacol. 2019 Feb;85(2):366-376. doi: 10.1111/bcp.13802. Epub 2018 Nov 22.</citation>
    <PMID>30362146</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 30, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <results_first_submitted>July 9, 2021</results_first_submitted>
  <results_first_submitted_qc>July 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2021</results_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ropinirole</keyword>
  <keyword>hyperprolactinemia</keyword>
  <keyword>prolactin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolactinoma</mesh_term>
    <mesh_term>Hyperprolactinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropinirole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03038308/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1 Subject was determined to be ineligible after consenting.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ROP Intervention</title>
          <description>Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study&#xD;
Ropinirole: 0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only 15 out of 16 enrolled subjects went on to receive study therapy; however, demographic information was collected for all 16 enrolled subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>ROP Intervention</title>
          <description>Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study&#xD;
Ropinirole: 0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects That Achieved Stable PRL Normalization</title>
        <description>Serum prolactin concentrations (PRL levels) were measured in patients at baseline and at follow-up.</description>
        <time_frame>6-12 months</time_frame>
        <population>Data for 10 out of 11 completers were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ROP Intervention</title>
            <description>Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study&#xD;
Ropinirole: 0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects That Achieved Stable PRL Normalization</title>
          <description>Serum prolactin concentrations (PRL levels) were measured in patients at baseline and at follow-up.</description>
          <population>Data for 10 out of 11 completers were included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unchanged Tumor Size</title>
        <description>Radiologic assessment of tumor size before and after treatment will be made by MRI.</description>
        <time_frame>6-12 months</time_frame>
        <population>Data for 8 out of 11 completers with prolactinomas were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ROP Intervention</title>
            <description>Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study&#xD;
Ropinirole: 0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unchanged Tumor Size</title>
          <description>Radiologic assessment of tumor size before and after treatment will be made by MRI.</description>
          <population>Data for 8 out of 11 completers with prolactinomas were included in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ROP Intervention</title>
          <description>Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study&#xD;
Ropinirole: 0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gabrielle Page-Wilson, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-3725</phone>
      <email>gp2287@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

